Streetbeat News

Stock Prices

AMRN

Amarin Corporation has announced preliminary Q4 FY23 total revenues of $72M-$74M, surpassing the consensus estimate of $62.03M.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:12 pm

RNLX

Renalytix has announced that a real-world evidence study published after 12 months of follow-up shows that its KidneyIntelX in vitro prognostic testing is associated with clinical actions that significantly slow the progression of chronic kidney disease (CKD).

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:08 pm

TGTX

TG Therapeutics projects Q1 BRIUMVI U.S. net product revenue to be between $41M and $46M. For FY24, the company anticipates revenue to range from $220M to $260M.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:07 pm

RVLV

Goldman Sachs analyst Alexandra Steiger has initiated coverage on Revolve Group (NYSE:RVLV) with a Sell rating and set a price target of $12 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:07 pm

DOW

In the last three months, 6 analysts have provided neutral ratings on Dow (NYSE:DOW) with no bullish or bearish stances. The average 12-month price target is $54.83, slightly up from the previous $54.40. Analysts from Deutsche Bank, UBS, Barclays, RBC Capital, Citigroup, and B of A Securities have made various adjustments to their price targets and ratings, reflecting a mix of raised and lowered expectations. Dow Chemical, a global chemicals producer, has faced a revenue decline of -23.98% as of September 30, 2023, but shows strong profitability with a net margin of 2.8% and an ROE of 1.52%.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 12:01 pm

MRCY

Goldman Sachs analyst Noah Poponak has downgraded Mercury Systems (MRCY) from Neutral to Sell and reduced the price target from $37 to $24.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:00 pm

TTE

TotalEnergies SE (NYSE:TTE) has signed an agreement to acquire additional interests in two Namibian oil discovery blocks from Impact Oil and Gas Namibia. The deal involves a 10.5% interest in block 2913B and a 9.39% interest in block 2912, with TotalEnergies planning to share this with QatarEnergy. The transaction costs $99 million and will increase TotalEnergies' stakes to 45.25% in block 2913B and 42.5% in block 2912, while Impact retains a 9.5% interest in each. The deal is subject to approvals and is a strategic move towards the development of the Venus discovery.

Portfolio Pulse from Nabaparna Bhattacharya

January 10, 2024 | 11:58 am

AAPL

KeyBanc Capital Markets analyst Brandon Nispel maintains a Sector Weight rating on Apple Inc. (AAPL), citing concerns for a weaker-than-expected holiday quarter. Apple's hardware revenue is projected to grow 38% sequentially in the December quarter, below the historical average of 62% and consensus estimate of 41%. KeyBanc's First Look Data indicates a 27% month-over-month increase in indexed spending, which is also below the three-year average of 37%. However, iPhone sell-through met store expectations, with strong demand for the iPhone 15 Pro/Max and solid demand for the regular 15/Plus. Despite this, KeyBanc's data suggests below-average growth for Apple's fiscal Q1 2024. Apple's stock is considered fairly valued, trading at 18.3x 2025 adjusted EBITDA, and is expected to perform in line with the Nasdaq.

Portfolio Pulse from Shanthi Rexaline

January 10, 2024 | 11:57 am

AAGR

MSS

WBUY

The article identifies three consumer staples stocks that are considered oversold based on their Relative Strength Index (RSI) values, suggesting a potential buying opportunity. Webuy Global Ltd (WBUY) announced a strategic collaboration with Ohmyhome, but its stock fell 53% over the past month. Maison Solutions Inc. (MSS) reported Q2 results and strategic growth plans, yet its stock dropped 93% over the past month. African Agriculture Holdings Inc. (AAGR) secured a supply agreement with Dr. Kahn, but its stock decreased 7% over the past five days.

Portfolio Pulse from Avi Kapoor

January 10, 2024 | 11:54 am

ALC

Alcon (NYSE:ALC) announced positive topline results from Phase 3 trials of AR-15512, a treatment for dry eye disease, showing significant improvement in tear production. The trials met the primary endpoint with statistical significance, and secondary data indicated rapid and sustained benefits. AR-15512 was well tolerated with no serious adverse events. Alcon plans to file an NDA with the FDA in mid-2024. Following the news, ALC shares rose 4.55% in premarket trading.

Portfolio Pulse from Vandana Singh

January 10, 2024 | 11:53 am